{"groups":[{"description":"Patients receive gemcitabine hydrochloride and cisplatin as in arm I. Patients also receive bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab IV over 30-90 minutes every 21 days in the absence of disease progression or unacceptable toxicity.","id":"FG000","title":"Arm II (GCB)"},{"description":"Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and cisplatin IV and placebo IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive placebo IV over 30-90 minutes every 21 days in the absence of disease progression or unacceptable toxicity.","id":"FG001","title":"Arm I (GCP)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"15"},{"groupId":"FG001","numSubjects":"22"}],"type":"Did not start treatment"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"252"},{"groupId":"FG001","numSubjects":"254"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"237"},{"groupId":"FG001","numSubjects":"232"}],"comment":"Started treatment","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"15"},{"groupId":"FG001","numSubjects":"22"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}